Hepatitis c, chronic Trials in Hanover, Germany
Conditions / Hepatitis c, chronic / Hanover, Germany
Hepatitis c, chronic has been the subject of sustained clinical investigation across multiple research sites.
40 total trials for this combination
Showing top 10 of 40 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00703118 | A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment | COMPLETED | PHASE3 |
| NCT00087646 | REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy | COMPLETED | PHASE4 |
| NCT01168856 | An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens | TERMINATED | — |
| NCT01457768 | A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response | COMPLETED | — |
| NCT00516321 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease | COMPLETED | PHASE3 |
| NCT01457755 | Gilead Sustained Virologic Response (SVR) Registry | COMPLETED | — |
| NCT00394277 | A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C | COMPLETED | PHASE4 |
| NCT00077636 | ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. | COMPLETED | PHASE4 |
| NCT00529568 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease | COMPLETED | PHASE3 |
| NCT01271790 | A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | COMPLETED | PHASE2 |